A series of novel 3-O-(3-aryl-propenyl)clarithromycin derivatives were designed, synthesized and evaluated for their in vitro antibacterial activities. Regioselective allylation at 3-OH was efficiently achieved in the presence of 9-oxime ether, compared with 9-keto. Most of the side chains were identified as the 3-O-(3-aryl-Z-prop-1-enyl) group, not the expected 3-O-(3-aryl-E-prop-2-enyl) group. Some derivatives of this series showed improved activities against erythromycin-resistant Staphylococcus aureus and Staphylococcus pneumoniae compared with the reference compound, clarithromycin, but weaker activities against susceptible strains.
INTRODUCTION
Erythromycin, a 14-membered macrolide antibiotic, has been used safely and effectively against respiratory tract infections since 1952. However, owing to its acid-instability, clarithromycin (6-O-methylerythromycin) as the second-generation erythromycin was developed to address the problem of ketalization of the C-9 carbonyl group by the 6-OH group. 1 It is noted that regioselective methylation at 6-OH to yield clarithromycin was not achieved until the introduction of oxime ether in the 9-carbonyl group. 2 Similarly, new emerging cethromycin [3-oxo-6-O-(3-(3¢-quinolyl)-2-propenyl)erythromycin derivative] as the third-generation erythromycin was synthesized by regioselective allylation at 6-OH [3] [4] [5] to overcome the relatively recent issues associated with the development of bacterial resistance.
Most of the third-generation erythromycin, cethromycin included, shares two distinguishing structural features: first, cladinose is not an essential moiety for the antibacterial activity, and removal of cladinose can prevent the induction of resistance ( Figure 1 ). As a result, modification at 3-OH led to the emergence of ketolide, [3] [4] [5] [6] acylide, 7 bicyclolide, 8 anhydrolide, 9 2,3-enol-ether, 10 3-deoxy, 11 3-ether, 12 3,6-ketal 13 and 3,6-ether. 14 Second, an aryl side chain tethered to the erythronolide core is believed to be very important for the improvement of activities against erythromycin-resistant bacteria, due to the interaction with a secondary ribosomal binding site. 15 The results published were not ours. In the search for novel erythromycin derivatives against erythromycin-resistant bacteria, the allyl group was a very important one for various further modifications at 6-OH of erythromycin. 4, 5 To the best of our knowledge, the introduction of the allyl group at 3-OH of 14-membered macrolides was not disclosed yet, in addition to the recent modification of 16-membered macrolides, leucomycin. 16 
RESULTS AND DISCUSSION
Initially, we attempted to attach an allyl group to 3-OH of the 2¢-OAc-3-OH-6-O-methylerythromycin 11, 12-carbonate with the structure of 9-keto, but unfortunately it failed and the major product in the resulting mixture was identified as 10,11-anhydro-3-OH-6-O-methylerythromycin A after methanolysis. Later, we found that the introduction of 9-oxime ether could dramatically improve the selectivity of allylation at 3-OH. Thus, a facile synthesis of 3-O-allyl of clarithromycin was conducted as a lead compound. In this study, we report a novel series of macrolides: 3-O-(3-aryl-propenyl)clarithromycin derivatives, which we named alkylides.
The synthesis of the targeted alkylide 9 in five steps from the intermediate 3-OH-6-O-methylerythromycin 9-O-(2-chlorobenzyl) oxime 4 was outlined in Schemes 1 and 2. Compound 4 was obtained by the acidic hydrolysis of 2¢,4 00 -O-bis(trimethylsilyl) 6-O-methylerythromycin 9-O-(2-chlorobenzyl)oxime 3, 17 which was an important intermediate for the synthesis of clarithromycin. Next, acetylation at 2¢-OH of 4 was followed by carbonation at 11, 12-OH generated 6. Consequently, allylation at 3-OH was efficiently achieved in the presence of allyl bromide and KOtBu, and 7 was produced in high yield (95.2%). Thus, various hetero-aryl bromides were used to install To confirm the regioselectivity of 3-OH, compound 12 was synthesized without the protection of 11, 12-OH (Scheme 3). The results proved that the regioselective allylation of 5 was also conducted in good yield (85.7%) and, as indicated, the regioselectivity at 3-OH was mainly influenced by 9-oxime ether.
A combination of 1 H NMR, COSY, 13 C NMR and HRMS was used to analyze the structure of this series. Surprisingly, the NMR spectrum showed that the aryl side chains of 9b-9g and 12c-12f were characterized by predominant Z configuration (J¼6 Hz), such as the 1-phenyl (a mixture of Z/E: 10:4), 3-pyridyl, 5-pyrimidyl, 3-quinolyl, 4-isoquinolyl and 5-isoquinolyl groups, whereas the 5-indolyl 9h side chain had E configuration (J¼16 Hz). This was significantly different from the previous results of allylation at 6-OH. 4 Further study by X-ray crystallography of 9f disclosed that the allylic double bond isomerized from 2-position to 1-position, and the Heck-isomerization to furnish enol concomitantly resulted in Z configuration, as shown in Figure 2 . Therefore, with the exception of 9h, the real structure of 9b-9g and 12c-12f should be the 3-O-(3-aryl-Z-prop-1-enyl)clarithromycin derivatives, not the expected 3-O-(3-aryl-E-prop-2-enyl)clarithromycin derivatives.
The in vitro antibacterial activity of alkylides 9 and 12 was assessed against erythromycin-susceptible and erythromycin-resistant bacteria, including Staphylococcus aureus and Streptococcus pneumoniae. Data are represented in Table 1 as the minimal inhibitory concentration, which is determined by the broth microdilution method as recommended by the NCCLS (National Committee of Clinical Laboratory Standard). 18 Some of the alkylides such as 9, 12 showed improved activities compared with the reference compound, clarithromycin, against resistant pathogens, particularly for S. aureus. Among them, 9d and 12d (3-pyrimidinyl) were promising candidates. The compounds with the mono-heteroaryl ring (9c-9d, 12c-12d) and the parent compounds 9a and 12a (H) possessed better activity against resistant pathogens than did those with fused aryl rings (9e-9h, 12e-12f). The crystal structure of 9f (4-isoquinolyl) disclosed that the fused aryl rings, regardless of the location of the nitrogen (e-g), may sterically prevent the 3¢-dimethylamino group from approaching the binding site, resulting in a decrease in activities. Compounds 9c, 12c (3-pyridyl) and 9d, 12d (3-pyrimidinyl) showed better activities than did the parent compounds 9a and 12a (H) against erythromycin-susceptible pathogens, but unfortunately no significant difference was found between them against erythromycin-resistant pathogens.
In conclusion, the 3-O-allyl clarithromycin derivative was synthesized in high regioselectivity to serve as a template. The introduction of the 3-O-aryl-propenyl group led to the acquisition of activities against erythromycin-resistant pathogens than reference compound, clarithromycin. The further chemical modification to improve activities is ongoing.
EXPERIMENTAL SECTION
All solvents and reagents were obtained from commercial sources and used without further purification unless otherwise noted. Column chromatography was performed on silica gel (200-300 mesh for 8 and 300-400 mesh for 9). 1 H and 13 C NMR spectra were recorded in CDCl 3 on a Bruker ARX 400 and 600 MHz (Bruker BioSpin AG Ltd, Beijing, China) with tetramethylsilane (TMS) as an internal standard. The assignments of 4, 7, 9c and 12a were made on the basis of D 2 O exchange and 1 H-1 H COSY. HRMS were obtained with Bruker Apex II ICRMS, or Bruker Apex IV FTMS.
To a solution of Erythromycin A, 9-O-oxime (10 g, 13.3 mmol) in acetonitrile (120 ml) was added 2-chlorobenzyl chloride (2.1 ml, 16.5 mmol) and KOH (1.3 g, 21 mmol). The reaction mixture was stirred at room temperature for 2 h, and in ice bath for another 1 h. The resulting precipitate was filtrated and dried to yield 1 (11.5 g, 98.6%).
2, 4¢¢-O-bis(trimethylsilyl)erythromycin A 9-O-(2-chlorobenzyl)oxime (2)
To a solution of 1 (23 g, 26.3 mmol) in acetonitrile (200 ml) was added pyridine hydrochloride (8.8 g, 76.1 mmol) and hexamethyldisilizane (HMDS) (20 ml, 94.2 mmol). The reaction mixture was stirred at room temperature for 1 h and extracted twice with petroleum ether. The organic phase was dried over MgSO 4 and evaporated to yield 2 (23.0 g, 85.8%). 13 
2¢, 4
00 -O-bis(trimethylsilyl)-6-O-methylerythromycin A 9-O-(2-chlorobenzyl)oxime (3)
To an ice-cold solution of 2 (23.0 g, 22.6 mmol) in 80 ml THF and 80 ml dimethyl sulfoxide (DMSO) was added CH 3 I (2.4 ml, 47.3 mmol) and KOH (2.4 g, 42.8 mmol). The reaction mixture was stirred at 01 C for 1 h, and then was poured with water and extracted with petroleum ether. The organic layer was concentrated to yield 3 (23.0 g, 98.6%).
3-OH-6-O-methylerythromycin A 9-O-(2-chlorobenzyl)oxime (4)
To a solution of 3 (23.0 g, 22.3 mmol) in ethanol (80 ml) was slowly added a solution of diluted HCl (8 ml HCl in 80 ml water) over 10 min. The reaction mixture was stirred at room temperature for 1.5 h and neutralized with NH 3 ÁH 2 O (36%, 8 ml) 
2¢-O-Ac-3-OH-6-O-methylerythromycin A 9-O-(2-chlorobenzyl)oxime (5)
A solution of 4 (5.0 g, 6.9 mmol) in CH 2 Cl 2 (50 ml) was treated with acetic anhydride (1.7 ml, 17.9 mmol) at room temperature for 1 h. The reaction mixture was washed with saturated NaHCO 3 and brine. The organic layer was dried over MgSO 4 and evaporated to yield 5 (5.0 g, 94.5%). 
2¢-O-Ac-3-OH-6-O-methylerythromycin A 9-O-(2-chlorobenzyl)oxime 11,12-carbonate (6)
To an ice-cold solution of 5 (4.8 g, 6.3 mmol) in CH 2 Cl 2 (120 ml) was added pyridine (5.0 ml, 61.9 mmol) and dropped by a solution of Bis(trichloromethyl)carbonate (3.73 g, 12.5 mmol)in CH 2 Cl 2 (60 ml) over 1 h. The reaction mixture was stirred at room temperature for 18 h and then cooled to 0 1C. To the reaction mixture was added dropwise water (100 ml). The organic layer was washed with saturated NaHCO 3 and water, and then dried over MgSO 4 and evaporated to yield 6 (4.9 g, 98.7%).
2¢-O-Ac-3-O-allyl-6-O-methylerythromycin A 9-O-(2-chlorobenzyl)oxime 11,12-carbonate (7) To an ice-cold solution of 6 (2.0 g, 2.5 mmol) in 20 ml of DMSO and 20 ml THF was added allyl bromide (0.42 ml, 5.0 mmol) and KOtBu (0.56 g, 5.0 mmol). The reaction mixture was stirred for 30 min, and then poured with water and extracted with ethyl acetate. The organic phase was washed with water and brine. [7.19-7.25 
By a similar prodedure to 9e, 8g was prepared as a white solid in 18.0% yield according to the general procedure for the preparation of 8e, and then deacetylated to give 9g (52.3% 
